Efficacy and Safety of Ide-Cel Confirmed in Real-World Multiple Myeloma Population
Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.
Diagnosis & Disease Information
Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma.
Daratumumab Extends OS in Relapsed/Refractory Multiple Myeloma
Adding daratumumab to lenalidomide and dexamethasone extends overall survival in relapsed/refractory multiple myeloma, according to final results from the POLLUX trial.
KCd Inferior to Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Researchers sought to determine whether a transplant-free regimen of KCd with carfilzomib maintenance would have similar efficacy to HSCT in multiple myeloma.
Novel Risk Prediction Tool May Identify Patients With Multiple Myeloma at a High Risk of Venous Thromboembolism
Researchers sought to determine whether the PRISM score would be able to identify patients with multiple myeloma at a high risk of VTE.
Dexamethasone-Sparing Regimen Shows Promise in Frail Patients With MM
A dexamethasone-sparing treatment strategy is safe and effective for frail patients with newly diagnosed multiple myeloma, according to researchers.
Circulating Leukocyte DNA Methylation Level May Be a Novel Biomarker in Multiple Myeloma
Researchers sought to determine whether DNA methylation in PBMCs could be a novel biomarker in multiple myeloma.
Geriatric Assessment in Hematology Scale Predicts Treatment Tolerability in Older Patients With Hematological Malignancies
Researchers sought to assess the geriatric assessment in hematology scale in older patients diagnosed with hematological malignancies.
Teclistamab Plus Daratumumab and Lenalidomide Shows Promise in Rel/Ref Multiple Myeloma
Teclistamab plus daratumumab and lenalidomide produced deep and durable responses in patients with relapsed or refractory multiple myeloma.
Talquetamab Elicits Responses in Relapsed/Refractory Multiple Myeloma
Talquetamab produced responses in more than 70% of patients with relapsed/refractory multiple myeloma who received the recommended phase 2 doses.
- Loading...
Loading...
Next post in Myeloma
Loading... 
Loading...